How much funding has Rectify raised?

Rectify has raised $100.0M in total funding, most recently a Series A round.

Who are Rectify's investors?

Rectify's investors include Atlas Venture, Omega Funds, Forbion Capital Partners, Longwood Fund.

Where is Rectify headquartered?

Rectify is headquartered in Cambridge, Massachusetts, United States.

What industry is Rectify in?

Rectify operates in Biotech, Healthcare.

Rectify

Rectifying function, Restoring hope

Cambridge, United States · Founded 2020 · $100.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: rectifypharma.com
Total Funding: $100.0M
Last Round: $100.0M Series AOct 2021
Rounds: 1

About

Rectify Pharma is a clinical-stage biotech company developing Positive Functional Modulators (PFMs), a novel class of oral small-molecule therapies designed to restore and enhance membrane protein function. Its proprietary platform targets ATP-binding cassette (ABC) transporters and other membrane proteins implicated in rare genetic and common diseases. The company's lead program is focused on primary sclerosing cholangitis (PSC), with additional pipeline programs in cardio-renal-metabolic diseases and neurology.

Summary

Rectify is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $100.0M in total across 1 round, most recently a $100.0M Series A round in Oct 2021. Investors include Atlas Venture, Omega Funds and Forbion Capital Partners.